These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 27570116)

  • 21. Neoadjuvant Therapy of Pancreatic Cancer: Definitions and Benefits.
    Heinrich S; Lang H
    Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28933761
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low lymphocyte monocyte ratio after neoadjuvant therapy predicts poor survival after pancreatectomy in patients with borderline resectable pancreatic cancer.
    Kawai M; Hirono S; Okada KI; Miyazawa M; Shimizu A; Kitahata Y; Kobayashi R; Ueno M; Hayami S; Tanioka K; Yamaue H
    Surgery; 2019 Jun; 165(6):1151-1160. PubMed ID: 30765142
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The cost-effectiveness of neoadjuvant chemoradiation is superior to a surgery-first approach in the treatment of pancreatic head adenocarcinoma.
    Abbott DE; Tzeng CW; Merkow RP; Cantor SB; Chang GJ; Katz MH; Bentrem DJ; Bilimoria KY; Crane CH; Varadhachary GR; Abbruzzese JL; Wolff RA; Lee JE; Evans DB; Fleming JB
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S500-8. PubMed ID: 23397153
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimal management of high-risk T1G3 bladder cancer: a decision analysis.
    Kulkarni GS; Finelli A; Fleshner NE; Jewett MA; Lopushinsky SR; Alibhai SM
    PLoS Med; 2007 Sep; 4(9):e284. PubMed ID: 17896857
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adjuvant and neoadjuvant therapies in resectable pancreatic cancer: a systematic review of randomized controlled trials.
    D'Angelo FA; Antolino L; La Rocca M; Petrucciani N; Magistri P; Aurello P; Ramacciato G
    Med Oncol; 2016 Mar; 33(3):28. PubMed ID: 26883935
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neoadjuvant therapy versus upfront surgery for resected pancreatic adenocarcinoma: A nationwide propensity score matched analysis.
    de Geus SW; Eskander MF; Bliss LA; Kasumova GG; Ng SC; Callery MP; Tseng JF
    Surgery; 2017 Mar; 161(3):592-601. PubMed ID: 28341441
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Neoadjuvant treatment of primarily resectable and borderline resectable pancreatic cancer].
    Scheufele F; Friess H
    Chirurg; 2020 May; 91(5):391-395. PubMed ID: 31965198
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Oncological Stress Test of Neoadjuvant Therapy: A Systematic Review in Outcomes of Neoadjuvant Therapy Compared to Upfront Resection Approach for Borderline Resectable Pancreatic Adenocarcinoma.
    Ross SB; Popover J; Sucandy I; Christodoulou M; Pattilachan TM; Rosemurgy AS
    Am Surg; 2024 Apr; ():31348241248703. PubMed ID: 38635295
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Radiographic patterns of first disease recurrence after neoadjuvant therapy and surgery for patients with resectable and borderline resectable pancreatic cancer.
    Barnes CA; Aldakkak M; Christians KK; Clarke CN; Dua K; George B; Ritch PS; Kamgar M; Hall WA; Kulkarni N; Erickson BA; Evans DB; Tsai S
    Surgery; 2020 Sep; 168(3):440-447. PubMed ID: 32641278
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neoadjuvant Treatment Versus Upfront Surgery in Resectable Pancreatic Cancer: A Cost-Effectiveness Analysis.
    Arjani S; Prasath V; Suri N; Li S; Ahlawat S; Chokshi RJ
    JCO Oncol Pract; 2023 Mar; 19(3):e439-e448. PubMed ID: 36548928
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial.
    Murphy JE; Wo JY; Ryan DP; Jiang W; Yeap BY; Drapek LC; Blaszkowsky LS; Kwak EL; Allen JN; Clark JW; Faris JE; Zhu AX; Goyal L; Lillemoe KD; DeLaney TF; Fernández-Del Castillo C; Ferrone CR; Hong TS
    JAMA Oncol; 2018 Jul; 4(7):963-969. PubMed ID: 29800971
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nonoperative Management Versus Radical Surgery of Rectal Cancer After Neoadjuvant Therapy-Induced Clinical Complete Response: A Markov Decision Analysis.
    de Buck van Overstraeten A; Khorasani S; Kennedy E; Look Hong NJ
    Dis Colon Rectum; 2020 Aug; 63(8):1080-1089. PubMed ID: 32398412
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neoadjuvant therapy offers longer survival than upfront surgery for poorly differentiated and higher stage pancreatic cancer.
    Nurmi A; Mustonen H; Parviainen H; Peltola K; Haglund C; Seppänen H
    Acta Oncol; 2018 Jun; 57(6):799-806. PubMed ID: 29241394
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical Impact of Neoadjuvant Chemotherapy and Chemoradiotherapy in Borderline Resectable Pancreatic Cancer: Analysis of 884 Patients at Facilities Specializing in Pancreatic Surgery.
    Nagakawa Y; Sahara Y; Hosokawa Y; Murakami Y; Yamaue H; Satoi S; Unno M; Isaji S; Endo I; Sho M; Fujii T; Takishita C; Hijikata Y; Suzuki S; Kawachi S; Katsumata K; Ohta T; Nagakawa T; Tsuchida A
    Ann Surg Oncol; 2019 Jun; 26(6):1629-1636. PubMed ID: 30610555
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer.
    Shrestha B; Sun Y; Faisal F; Kim V; Soares K; Blair A; Herman JM; Narang A; Dholakia AS; Rosati L; Hacker-Prietz A; Chen L; Laheru DA; De Jesus-Acosta A; Le DT; Donehower R; Azad N; Diaz LA; Murphy A; Lee V; Fishman EK; Hruban RH; Liang T; Cameron JL; Makary M; Weiss MJ; Ahuja N; He J; Wolfgang CL; Huang CY; Zheng L
    Cancer Med; 2017 Jul; 6(7):1552-1562. PubMed ID: 28639410
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer: A Propensity Score Matched Analysis.
    Mokdad AA; Minter RM; Zhu H; Augustine MM; Porembka MR; Wang SC; Yopp AC; Mansour JC; Choti MA; Polanco PM
    J Clin Oncol; 2017 Feb; 35(5):515-522. PubMed ID: 27621388
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neoadjuvant therapy for patients with borderline resectable pancreatic cancer: A systematic review and meta-analysis of response and resection percentages.
    Tang K; Lu W; Qin W; Wu Y
    Pancreatology; 2016; 16(1):28-37. PubMed ID: 26687001
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intention to treat outcomes among patients with pancreatic cancer treated using International Study Group on Pancreatic Surgery recommended pathways for resectable and borderline resectable disease.
    Kamarajah SK; Chatzizacharias N; Hodson J; Marcon F; Kalisvaart M; Punia P; Ting Ma Y; Dasari B; Marudanayagam R; Sutcliffe RP; Muiesan P; Mirza DF; Isaac J; Roberts KJ
    ANZ J Surg; 2021 Jul; 91(7-8):1549-1557. PubMed ID: 33576568
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preoperative MDCT Assessment of Resectability in Borderline Resectable Pancreatic Cancer: Effect of Neoadjuvant Chemoradiation Therapy.
    Joo I; Lee JM; Lee ES; Ahn SJ; Lee DH; Kim SW; Ryu JK; Oh DY; Kim K; Lee KB; Jang JY
    AJR Am J Roentgenol; 2018 May; 210(5):1059-1065. PubMed ID: 29489408
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative Effectiveness of Neoadjuvant Therapy and Upfront Resection for Patients with Resectable Pancreatic Adenocarcinoma: An Instrumental Variable Analysis.
    da Costa WL; Tran Cao HS; Sheetz KH; Gu X; Norton EC; Massarweh NN
    Ann Surg Oncol; 2021 Jun; 28(6):3186-3195. PubMed ID: 33174146
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.